Maravai Lifesciences Holdings (MRVI)
Maravai Lifesciences Holdings on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
13.3M
Short interest
settlement 2026-10-15
4.5
Days to cover
-1.5 days vs prior
33.3%
Short share of volume
2026-11-03
104,952
Fails to deliver
settlement 2026-10-14
Thu 5 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-03.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in MRVI is 13,348,935 shares, up 976,633 shares over the last month. Over the last 48 readings it ranged from 6,962,636 shares (15 November 2024) to 14,595,684 shares (15 May 2025). At the reported average volume of 3.0M shares a day that is 4.5 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/mrvi" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 13,348,935 | -3.5% | 3,000,401 | 4.45 |
| 2026-09-30 | 13,826,066 | +11.8% | 2,341,522 | 5.90 |
| 2026-09-15 | 12,372,302 | +12.8% | 2,660,842 | 4.65 |
| 2026-08-31 | 10,963,180 | +16.9% | 6,614,983 | 1.66 |
| 2026-08-14 | 9,382,604 | +10.3% | 2,035,313 | 4.61 |
| 2026-07-31 | 8,510,416 | -8.2% | 2,347,218 | 3.63 |
| 2026-07-15 | 9,271,035 | +5.2% | 3,114,799 | 2.98 |
| 2026-06-30 | 8,814,048 | +1.9% | 3,784,665 | 2.33 |
| 2026-06-15 | 8,652,421 | +9.9% | 2,918,403 | 2.96 |
| 2026-05-29 | 7,874,103 | -7.5% | 2,665,309 | 2.95 |
| 2026-05-15 | 8,514,671 | -4.1% | 3,190,286 | 2.67 |
| 2026-04-30 | 8,882,808 | -3.9% | 1,794,925 | 4.95 |
| 2026-04-15 | 9,244,441 | -2.8% | 1,905,453 | 4.85 |
| 2026-03-31 | 9,510,334 | -2.2% | 2,038,367 | 4.67 |
| 2026-03-13 | 9,722,307 | -8.6% | 1,477,075 | 6.58 |
| 2026-02-27 | 10,636,080 | -2.9% | 1,116,684 | 9.52 |
| 2026-02-13 | 10,953,646 | -2.9% | 1,086,041 | 10.09 |
| 2026-01-30 | 11,285,965 | -8.1% | 1,027,535 | 10.98 |
| 2026-01-15 | 12,282,727 | +6.3% | 1,215,507 | 10.11 |
| 2025-12-31 | 11,555,500 | -9.4% | 1,166,213 | 9.91 |
| 2025-12-15 | 12,756,177 | +3.9% | 1,334,619 | 9.56 |
| 2025-11-28 | 12,278,685 | -7.6% | 1,478,645 | 8.30 |
| 2025-11-14 | 13,282,908 | +2.3% | 1,587,361 | 8.37 |
| 2025-10-31 | 12,985,865 | -3.3% | 1,308,683 | 9.92 |
| 2025-10-15 | 13,427,916 | +2.5% | 2,040,241 | 6.58 |
| 2025-09-30 | 13,095,291 | -8.9% | 1,358,410 | 9.64 |
| 2025-09-15 | 14,381,380 | +3.6% | 1,040,199 | 13.83 |
| 2025-08-29 | 13,879,316 | +2.9% | 870,759 | 15.94 |
| 2025-08-15 | 13,495,101 | +1.4% | 1,937,907 | 6.96 |
| 2025-07-31 | 13,310,622 | -7.4% | 1,349,138 | 9.87 |
| 2025-07-15 | 14,380,643 | +4.6% | 1,780,771 | 8.08 |
| 2025-06-30 | 13,753,559 | +5.4% | 2,246,061 | 6.12 |
| 2025-06-13 | 13,048,449 | -4.6% | 1,418,249 | 9.20 |
| 2025-05-30 | 13,673,649 | -6.3% | 1,777,555 | 7.69 |
| 2025-05-15 | 14,595,684 | +2.5% | 1,965,788 | 7.42 |
| 2025-04-30 | 14,244,004 | +2.1% | 1,722,415 | 8.27 |
| 2025-04-15 | 13,951,884 | +6.2% | 2,920,382 | 4.78 |
| 2025-03-31 | 13,133,915 | +13.2% | 4,122,477 | 3.19 |
| 2025-03-14 | 11,604,523 | +31.5% | 3,643,817 | 3.18 |
| 2025-02-28 | 8,822,415 | -14.3% | 5,625,048 | 1.57 |
| 2025-02-14 | 10,300,517 | +20.6% | 1,979,144 | 5.20 |
| 2025-01-31 | 8,540,093 | -4.2% | 1,994,211 | 4.28 |
| 2025-01-15 | 8,918,685 | +4.8% | 2,202,968 | 4.05 |
| 2024-12-31 | 8,507,989 | +2.6% | 1,458,512 | 5.83 |
| 2024-12-13 | 8,292,875 | +4.9% | 1,512,946 | 5.48 |
| 2024-11-29 | 7,904,243 | +13.5% | 1,883,911 | 4.20 |
| 2024-11-15 | 6,962,636 | -15.3% | 3,254,565 | 2.14 |
| 2024-10-31 | 8,218,867 | -8.3% | 1,315,689 | 6.25 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 3 November 2026, the short share of MRVI volume is 33.3%, down 8.6 points over the last five sessions. Over the last 30 readings it ranged from 20.0% (28 October 2026) to 64.2% (26 October 2026). The latest reading is 9.5 points below the 30-session average of 42.8%, on 537K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-03 | 179K | 537K | 33.3% | 0 |
| 2026-11-02 | 186K | 819K | 22.8% | 7,895 |
| 2026-10-30 | 286K | 614K | 46.6% | 0 |
| 2026-10-29 | 230K | 497K | 46.2% | 0 |
| 2026-10-28 | 257K | 1.3M | 20.0% | 0 |
| 2026-10-27 | 502K | 1.2M | 41.9% | 267 |
| 2026-10-26 | 198K | 309K | 64.2% | 352 |
| 2026-10-23 | 207K | 378K | 54.8% | 297 |
| 2026-10-22 | 611K | 1.5M | 41.6% | 17,536 |
| 2026-10-21 | 272K | 456K | 59.7% | 0 |
| 2026-10-20 | 375K | 838K | 44.8% | 0 |
| 2026-10-19 | 237K | 376K | 63.1% | 405 |
| 2026-10-16 | 302K | 602K | 50.1% | 203 |
| 2026-10-15 | 314K | 768K | 40.8% | 0 |
| 2026-10-14 | 268K | 1.1M | 25.2% | 0 |
| 2026-10-13 | 319K | 1.5M | 22.0% | 440 |
| 2026-10-12 | 237K | 504K | 46.9% | 953 |
| 2026-10-09 | 289K | 689K | 42.0% | 80 |
| 2026-10-08 | 348K | 1.1M | 30.3% | 0 |
| 2026-10-07 | 326K | 1.1M | 29.8% | 4,211 |
| 2026-10-06 | 739K | 1.7M | 43.2% | 12 |
| 2026-10-05 | 461K | 1.0M | 44.6% | 4,315 |
| 2026-10-02 | 367K | 712K | 51.5% | 1,115 |
| 2026-10-01 | 469K | 1.0M | 45.1% | 2,121 |
| 2026-09-30 | 296K | 784K | 37.7% | 0 |
| 2026-09-29 | 313K | 634K | 49.4% | 0 |
| 2026-09-28 | 227K | 485K | 46.8% | 0 |
| 2026-09-25 | 350K | 706K | 49.6% | 0 |
| 2026-09-24 | 455K | 849K | 53.5% | 0 |
| 2026-09-23 | 172K | 472K | 36.4% | 96 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in MRVI is 104,952 shares, up 104,948 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (22 April 2026) to 104,952 shares (14 October 2026). The latest reading sits at the top of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 104,952 | $6.53 | $685K |
| 2026-10-13 | 4 | $7.06 | $28 |
| 2026-10-08 | 2,087 | $7.43 | $16K |
| 2026-09-03 | 7,459 | $7.38 | $55K |
| 2026-09-02 | 1,319 | $7.30 | $10K |
| 2026-08-24 | 500 | $8.64 | $4K |
| 2026-08-17 | 524 | $5.70 | $3K |
| 2026-08-12 | 768 | $5.81 | $4K |
| 2026-08-06 | 264 | $6.41 | $2K |
| 2026-08-05 | 449 | $6.43 | $3K |
| 2026-08-03 | 46 | $6.57 | $302 |
| 2026-07-28 | 3 | $6.69 | $20 |
| 2026-07-22 | 4,364 | $7.10 | $31K |
| 2026-07-13 | 3 | $6.09 | $18 |
| 2026-07-06 | 34 | $6.04 | $205 |
| 2026-07-02 | 8 | $6.15 | $49 |
| 2026-07-01 | 642 | $6.24 | $4K |
| 2026-06-30 | 252 | $6.39 | $2K |
| 2026-06-29 | 25 | $6.22 | $156 |
| 2026-06-24 | 252 | $5.37 | $1K |
| 2026-06-12 | 26,205 | $5.21 | $137K |
| 2026-06-04 | 44,125 | $4.84 | $214K |
| 2026-05-27 | 6,497 | $4.38 | $28K |
| 2026-05-26 | 6,496 | $4.40 | $29K |
| 2026-05-19 | 177 | $4.08 | $722 |
| 2026-05-06 | 619 | $3.85 | $2K |
| 2026-05-04 | 7,768 | $3.73 | $29K |
| 2026-04-22 | 1 | $3.68 | $4 |
| 2026-04-09 | 3,799 | $3.11 | $12K |
| 2026-04-06 | 2,083 | $2.95 | $6K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for MRVI in the last 90 days. The most recent filings are listed below. Latest filing: Asarpota Rajesh (Chief Financial Officer) on 2026-10-30.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-30 | Asarpota Rajesh | Chief Financial Officer | Tax withholding | 5K | $8.46 | $46K | 286K |
| 2026-10-08 | Brust Bernd | Chief Executive Officer | Tax withholding | 29K | $7.43 | $217K | 1.5M |
| 2026-09-30 | Asarpota Rajesh | Chief Financial Officer | Tax withholding | 5K | $7.65 | $42K | 418K |
| 2026-09-08 | Brust Bernd | Chief Executive Officer | Tax withholding | 29K | $7.32 | $214K | 1.6M |
| 2026-08-31 | Asarpota Rajesh | Chief Financial Officer | Tax withholding | 5K | $7.68 | $42K | 423K |
| 2026-08-10 | Brust Bernd | Chief Executive Officer | Tax withholding | 29K | $6.23 | $182K | 1.6M |
| 2026-07-30 | Asarpota Rajesh | Chief Financial Officer | Tax withholding | 5K | $6.59 | $36K | 429K |
| 2026-07-08 | Brust Bernd | Chief Executive Officer | Tax withholding | 29K | $5.92 | $173K | 1.6M |
| 2026-06-30 | Asarpota Rajesh | Chief Financial Officer | Tax withholding | 66K | $6.39 | $419K | 434K |
| 2026-06-10 | ORESHACK KURT | General Counsel | Sell | 25K | $5.10 | $128K | 336K |
| 2026-06-09 | LUCIER GREGORY T | Director | Gift | 46K | $0.00 | $0 | 156K |
| 2026-06-09 | ORESHACK KURT | General Counsel | Sell | 25K | $5.06 | $127K | 361K |
| 2026-06-09 | LUCIER GREGORY T | Director | Gift | 46K | $0.00 | $0 | 155K |
| 2026-06-08 | Brust Bernd | Chief Executive Officer | Tax withholding | 351K | $5.02 | $1.8M | 1.6M |
| 2026-05-26 | LUCIER GREGORY T | Director | Grant | 46K | $0.00 | $0 | 201K |
| 2026-05-26 | MARKER LUKE JOSEPH | Director | Grant | 46K | $0.00 | $0 | 184K |
| 2026-05-26 | MIHAS CONSTANTINE S | Director | Grant | 46K | $0.00 | $0 | 184K |
| 2026-05-26 | LUCIER GREGORY T | Director | Grant | 46K | $4.38 | $203K | 201K |
| 2026-05-26 | GRAY SUSANNAH | Director | Grant | 46K | $0.00 | $0 | 216K |
| 2026-05-26 | ECKERT R ANDREW | Director | Grant | 46K | $0.00 | $0 | 412K |
| 2026-05-26 | DeFord John A | Director | Grant | 46K | $0.00 | $0 | 205K |
| 2026-05-26 | CUNNINGHAM SEAN LAURENCE | Director | Grant | 46K | $0.00 | $0 | 184K |
| 2026-05-15 | ORESHACK KURT | General Counsel | Grant | 776 | $2.84 | $2K | 386K |
| 2026-05-15 | Dolan Christine | See Remarks | Grant | 5K | $1.79 | $9K | 425K |
| 2026-03-16 | ORESHACK KURT | General Counsel | Tax withholding | 40K | $3.08 | $123K | 385K |
| 2026-03-16 | Dolan Christine | See Remarks | Tax withholding | 29K | $3.08 | $88K | 420K |
| 2026-01-15 | ORESHACK KURT | General Counsel | Tax withholding | 32K | $3.69 | $118K | 425K |
| 2026-01-15 | Dolan Christine | See Remarks | Tax withholding | 29K | $3.69 | $107K | 449K |
| 2025-12-08 | LUCIER GREGORY T | Director | Buy | 49K | $3.67 | $178K | 155K |
| 2025-12-05 | LUCIER GREGORY T | Director | Buy | 51K | $3.70 | $190K | 107K |
| 2025-11-14 | Dolan Christine | See Remarks | Grant | 4K | $1.79 | $8K | 478K |
| 2025-11-13 | Brust Bernd | Chief Executive Officer | Buy | 216K | $3.25 | $703K | 467K |
| 2025-11-12 | Brust Bernd | Chief Executive Officer | Buy | 93K | $3.21 | $300K | 251K |
| 2025-11-11 | Brust Bernd | Chief Executive Officer | Buy | 157K | $3.24 | $509K | 157K |
| 2025-07-15 | Leddy Peter Michael | See Remarks | Tax withholding | 5K | $2.59 | $13K | 727K |
| 2025-07-10 | LUCIER GREGORY T | Director | Gift | 89K | $0.00 | $0 | 110K |
| 2025-07-10 | LUCIER GREGORY T | Director | Gift | 89K | $0.00 | $0 | 55K |
| 2025-06-30 | Asarpota Rajesh | Chief Financial Officer | Grant | 500K | price not stated in the filing | not stated | 500K |
| 2025-06-16 | MARKER LUKE JOSEPH | Director | Grant | 89K | $2.16 | $193K | 138K |
| 2025-06-16 | PRAHALAD MURALI | Director | Grant | 89K | $2.16 | $193K | 155K |
| 2025-06-16 | MIHAS CONSTANTINE S | Director | Grant | 89K | $2.16 | $193K | 138K |
| 2025-06-16 | LUCIER GREGORY T | Director | Grant | 89K | $2.16 | $193K | 144K |
| 2025-06-16 | Hopfield Jessica | Director | Grant | 89K | $2.16 | $193K | 200K |
| 2025-06-16 | GRAY SUSANNAH | Director | Grant | 89K | $2.16 | $193K | 170K |
| 2025-06-16 | ECKERT R ANDREW | Director | Grant | 231K | $2.16 | $500K | 366K |
| 2025-06-16 | DeFord John A | Director | Grant | 89K | $2.16 | $193K | 159K |
| 2025-06-16 | DAVERMAN BENJAMIN JAMES | Director | Grant | 89K | $2.16 | $193K | 138K |
| 2025-06-16 | CUNNINGHAM SEAN LAURENCE | Director | Grant | 89K | $2.16 | $193K | 138K |
| 2025-06-08 | Brust Bernd | Chief Executive Officer | Grant | 2.0M | price not stated in the filing | not stated | 2.0M |
| 2025-05-15 | Dolan Christine | See Remarks | Grant | 2K | $1.67 | $4K | 474K |
| 2025-05-15 | Herde Kevin | Chief Financial Officer | Grant | 876 | $1.67 | $1K | 675K |
| 2025-03-17 | BUZZEO REBECCA | See Remarks | Tax withholding | 4K | $2.64 | $11K | 311K |
| 2025-03-17 | Dolan Christine | See Remarks | Tax withholding | 5K | $2.64 | $14K | 225K |
| 2025-03-17 | ORESHACK KURT | General Counsel | Tax withholding | 5K | $2.64 | $12K | 161K |
| 2025-03-17 | Leddy Peter Michael | See Remarks | Tax withholding | 6K | $2.64 | $16K | 338K |
| 2025-03-17 | Herde Kevin | Chief Financial Officer | Tax withholding | 9K | $2.64 | $23K | 279K |
| 2025-03-17 | Dolan Christine | See Remarks | Grant | 247K | price not stated in the filing | not stated | 471K |
| 2025-03-17 | MARTIN WILLIAM E. III | Chief Executive Officer | Grant | 986K | price not stated in the filing | not stated | 1.8M |
| 2025-03-17 | Leddy Peter Michael | See Remarks | Grant | 394K | price not stated in the filing | not stated | 732K |
| 2025-03-17 | BUZZEO REBECCA | See Remarks | Grant | 296K | price not stated in the filing | not stated | 607K |
| 2025-03-17 | ORESHACK KURT | General Counsel | Grant | 296K | price not stated in the filing | not stated | 457K |
| 2025-03-17 | Herde Kevin | Chief Financial Officer | Grant | 394K | price not stated in the filing | not stated | 674K |
| 2025-02-18 | Herde Kevin | Chief Financial Officer | Tax withholding | 2K | $4.10 | $10K | 288K |
| 2025-02-18 | Dolan Christine | See Remarks | Tax withholding | 2K | $4.10 | $7K | 230K |
| 2025-02-18 | ORESHACK KURT | General Counsel | Tax withholding | 2K | $4.10 | $8K | 166K |
| 2025-01-31 | ORESHACK KURT | General Counsel | Sell | 25K | $5.03 | $126K | 168K |
| 2025-01-15 | Leddy Peter Michael | See Remarks | Tax withholding | 32K | $4.56 | $146K | 344K |
| 2025-01-15 | Dolan Christine | See Remarks | Tax withholding | 29K | $4.56 | $131K | 232K |
| 2025-01-15 | ORESHACK KURT | General Counsel | Tax withholding | 31K | $4.56 | $143K | 193K |
| 2025-01-15 | BUZZEO REBECCA | See Remarks | Tax withholding | 45K | $4.56 | $207K | 315K |
| 2025-01-15 | BURCH ANDREW | See Remarks | Tax withholding | 54K | $4.56 | $248K | 369K |
| 2025-01-15 | Herde Kevin | Chief Financial Officer | Tax withholding | 46K | $4.56 | $211K | 290K |
| 2025-01-15 | MARTIN WILLIAM E. III | Chief Executive Officer | Tax withholding | 161K | $4.56 | $734K | 828K |
| 2024-12-16 | ECKERT R ANDREW | Director | Grant | 134K | price not stated in the filing | not stated | 134K |
| 2024-12-09 | LUCIER GREGORY T | Director | Gift | 21K | $0.00 | $0 | 55K |
| 2024-12-09 | LUCIER GREGORY T | Director | Gift | 21K | $0.00 | $0 | 21K |
| 2024-11-15 | BUZZEO REBECCA | See Remarks | Tax withholding | 4K | $4.42 | $19K | 361K |
| 2024-11-12 | DeFord John A | Director | Buy | 18K | $5.75 | $101K | 70K |
| 2024-11-11 | HULL CARL | See Remarks | Buy | 175K | $5.64 | $987K | 175K |
| 2024-10-31 | BURCH ANDREW | See Remarks | Grant | 2K | $5.70 | $10K | 424K |
| 2024-10-31 | Dolan Christine | See Remarks | Grant | 2K | $5.70 | $11K | 260K |
| 2024-10-31 | ORESHACK KURT | General Counsel | Grant | 366 | $5.70 | $2K | 224K |
| 2024-10-31 | Herde Kevin | Chief Financial Officer | Grant | 2K | $5.70 | $11K | 337K |
| 2024-10-15 | MARTIN WILLIAM E. III | Chief Executive Officer | Tax withholding | 51K | $8.29 | $421K | 989K |
| 2024-07-15 | Leddy Peter Michael | See Remarks | Tax withholding | 5K | $8.76 | $45K | 376K |
| 2024-05-28 | MARAVAI LIFE SCIENCES HOLDINGS, LLC | Director,TenPercentOwner | Returned to company | 8.4M | price not stated in the filing | not stated | 110.7M |
| 2024-05-28 | MARAVAI LIFE SCIENCES HOLDINGS, LLC | Director,TenPercentOwner | Sell | 9.9M | $9.82 | $97.6M | 20.2M |
| 2024-05-28 | MARAVAI LIFE SCIENCES HOLDINGS, LLC | Director,TenPercentOwner | Conversion | 8.4M | price not stated in the filing | not stated | 30.1M |
| 2024-05-23 | LUCIER GREGORY T | Director | Grant | 21K | $10.78 | $223K | 76K |
| 2024-05-23 | GRAY SUSANNAH | Director | Grant | 21K | $10.78 | $223K | 81K |
| 2024-05-23 | DeFord John A | Director | Grant | 21K | $10.78 | $223K | 53K |
| 2024-05-23 | MARKER LUKE JOSEPH | Director | Grant | 21K | $10.78 | $223K | 49K |
| 2024-05-23 | Hopfield Jessica | Director | Grant | 21K | $10.78 | $223K | 111K |
| 2024-05-23 | DAVERMAN BENJAMIN JAMES | Director | Grant | 21K | $10.78 | $223K | 49K |
| 2024-05-23 | Ashkenazi Anat | Director | Grant | 21K | $10.78 | $223K | 61K |
| 2024-05-23 | PRAHALAD MURALI | Director | Grant | 21K | $10.78 | $223K | 65K |
| 2024-05-23 | CUNNINGHAM SEAN LAURENCE | Director | Grant | 21K | $10.78 | $223K | 49K |
| 2024-05-23 | MIHAS CONSTANTINE S | Director | Grant | 21K | $10.78 | $223K | 49K |
| 2024-04-30 | Leddy Peter Michael | See Remarks | Grant | 5K | $5.70 | $26K | 381K |
| 2024-04-30 | Dolan Christine | See Remarks | Grant | 483 | $5.70 | $3K | 258K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON4 Form 144 notices on file for MRVI worth $455K at the prices reported; 0 in the last 90 days worth $0. Latest: ORESHACK KURT filed on 2026-06-10 to sell 25,000 shares ($128K) from 2026-06-10.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-06-10 | ORESHACK KURTOfficer | 25K | $128K | 0.017% | 2026-06-10 | Fidelity Brokerage Services LLC |
| 2026-06-09 | ORESHACK KURTOfficer | 25K | $127K | 0.017% | 2026-06-09 | Fidelity Brokerage Services LLC |
| 2025-12-23 | PRAHALAD MURALIFormer Director | 4K | $13K | 0.003% | 2025-12-23 | Fidelity Brokerage Services LLC |
| 2025-12-19 | Hopfield JessicaFormer Director | 54K | $188K | 0.037% | 2025-12-19 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON4 holders report 5% or more of MRVI in their latest filing, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 5.9% of the class (8,580,553 shares), filed 2025-10-17 for an event on 2025-09-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-09-29 | 13G | Millennium Management LLCother entity | 7.8M | 5.2% | 2026-09-22 |
| 2026-09-29 | 13G | Millennium Group Management LLCother entity | 7.8M | 5.2% | 2026-09-22 |
| 2026-09-29 | 13G | Israel A. Englanderindividual | 7.8M | 5.2% | 2026-09-22 |
| 2026-08-13 | 13G/Ano. 4 | Stuart Feldmanindividual | 3.7M | 2.5% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | JD Squared Capital II LLCpartnership | 3.0M | 2.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | JD Squared Holdings II LLCpartnership | 3.0M | 2.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Hudson View Capital LLCpartnership | 674K | 0.5% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Hudson View Holdings LLCpartnership | 674K | 0.5% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Matthew Barkoffindividual | 290K | 0.2% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Joshua Woolindividual | 45K | 0.0% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 5 | Joel Raminparent holding company, individual | 7.3M | 4.9% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 5 | 12 West Capital Management LPinvestment adviser, partnership | 7.3M | 4.9% | 2026-03-31 |
| 2025-10-31 | 13G/Ano. 5 | The Vanguard Groupinvestment adviser | 7.1M | 4.9% | 2025-09-30 |
| 2025-10-17 | 13G/Ano. 1 | BlackRock, Inc.parent holding company | 8.6M | 5.9% | 2025-09-30 |
13F holders
Tracked managers holding MRVI at their latest 13F. JSON6 of the 30 tracked managers held MRVI at their latest 13F, $109.7M in total at quarter-end prices. Millennium Management is the largest at $40.6M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 6.5M | $40.6M | 0.01% | +4.9M |
| Renaissance Technologies | 2026-06-30 | 4.6M | $28.7M | 0.04% | +342K |
| Two Sigma Investments | 2026-06-30 | 2.3M | $14.1M | 0.01% | +676K |
| Citadel Advisors | 2026-06-30 | 2.1M | $13.2M | 0.00% | +638K |
| Point72 Asset Management | 2026-06-30 | 2.0M | $12.5M | 0.01% | -1.2M |
| AQR Capital Management | 2026-06-30 | 85K | $529K | 0.00% | +2K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Maravai Lifesciences Holdings reported revenue of $51.4M, up 8.5% from the same quarter a year earlier, and net loss of $12.4M (-0.08 diluted EPS). In FY 2025 it generated -$57.6M of operating cash flow. As of 2026-06-30, cash was $70.1M against $147.1M of debt.
- Cash
- $70.1M
- Debt
- $147.1M
- Equity
- $204.6M
- Total assets
- $603.7M
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $51.4M | -$12.4M | -24.1% | -0.08 |
| Q1 FY 2026 | 2026-03-31 | $65.8M | -$3.7M | -5.7% | -0.02 |
| Q4 FY 2025derived | 2025-12-31 | $49.9M | n/a | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | $41.6M | -$25.6M | -61.4% | -0.18 |
| Q2 FY 2025 | 2025-06-30 | $47.4M | -$39.6M | -83.5% | -0.27 |
| Q1 FY 2025 | 2025-03-31 | $46.9M | -$29.9M | -63.9% | -0.21 |
| Q4 FY 2024derived | 2024-12-31 | $56.6M | n/a | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | $69.0M | -$97.1M | -140.6% | -0.68 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $185.7M | -$130.8M | -$57.6M | $13.1M | n/a | n/a |
| FY 2024 | 2024-12-31 | $259.2M | -$144.8M | $7.5M | $29.7M | n/a | n/a |
| FY 2023 | 2023-12-31 | $288.9M | -$138.4M | $126.2M | $65.6M | n/a | n/a |
| FY 2022 | 2022-12-31 | $883.0M | $490.7M | $536.0M | $17.1M | $0 | n/a |
| FY 2021 | 2021-12-31 | $799.2M | $469.3M | $368.6M | $14.8M | $0 | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30.
What this page is
Maravai Lifesciences Holdings in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Maravai Lifesciences Holdings (MRVI), SEC CIK 1823239, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-03.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-06-10.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-09-29.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-30.JSON and CSV
- Company record
- EDGAR filing index for CIK 1823239Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of MRVI is sold short?
13,348,935 shares were held short at the 2026-10-15 settlement, 4.5 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is MRVI's daily short volume?
On 2026-11-03, 178,966 of the 536,837 MRVI shares reported to FINRA were sold short, 33.3% of the day's reported volume. Short volume is a flow for one day, not a position.
Does MRVI have fails to deliver?
The SEC's latest file shows 104,952 MRVI shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.
Are MRVI insiders buying or selling?
No open-market insider trades were reported for MRVI in the last 90 days. The most recent filings are listed below. Latest filing: Asarpota Rajesh (Chief Financial Officer) on 2026-10-30.
Have MRVI insiders filed to sell?
4 Form 144 notices on file for MRVI worth $455K at the prices reported; 0 in the last 90 days worth $0. Latest: ORESHACK KURT filed on 2026-06-10 to sell 25,000 shares ($128K) from 2026-06-10.
Who owns 5% or more of MRVI?
4 holders report 5% or more of MRVI in their latest filing, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 5.9% of the class (8,580,553 shares), filed 2025-10-17 for an event on 2025-09-30.
What did MRVI report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Maravai Lifesciences Holdings reported revenue of $51.4M, up 8.5% from the same quarter a year earlier, and net loss of $12.4M (-0.08 diluted EPS). In FY 2025 it generated -$57.6M of operating cash flow. As of 2026-06-30, cash was $70.1M against $147.1M of debt.
Which tracked 13F managers own MRVI?
6 of the 30 tracked 13F managers held MRVI shares at their latest filing, $109.7M in all. The largest: Izzy Englander's Millennium Management (6.5M shares, $40.6M), Renaissance Technologies (4.6M shares, $28.7M), Two Sigma Investments (2.3M shares, $14.1M), Ken Griffin's Citadel Advisors (2.1M shares, $13.2M), Steve Cohen's Point72 Asset Management (2.0M shares, $12.5M), Cliff Asness's AQR Capital Management (85K shares, $529K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.